SCHEMBL13663570

SCHEMBL13663570

Cc1cc(Nc2cncc(Nc3ccc4scnc4c3)n2)n[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 2/20 0.46
▸ JAK3 P52333 2/20 0.46
▸ AURKA O14965 4/20 0.42
▸ AURKB Q96GD4 4/20 0.42
▸ KDR P35968 4/20 0.42
▸ FLT4 P35916 2/20 0.42
▸ DHODH Q02127 1/20 0.41
▸ LRRK2 Q5S007 1/20 0.41
▸ RIPK2 O43353 6/20 0.39
▸ RIPK3 Q9Y572 2/20 0.39
▸ EGFR P00533 1/20 0.39
▸ INSR P06213 1/20 0.39
▸ IGF1R P08069 1/20 0.39
▸ SRC P12931 1/20 0.39
▸ PIK3CA P42336 1/20 0.38
▸ MTOR P42345 1/20 0.38
▸ ITK Q08881 1/20 0.38
▸ TRPM5 Q9NZQ8 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13663537 0.78 JAK2 (0.50) JAK2JAK3AURKAAURKBKDR
SCHEMBL13663574 0.78 DHODH (0.55) JAK2JAK3AURKAAURKBKDR
SCHEMBL13663495 0.77 JAK2 (0.62) JAK2JAK3AURKAAURKBKDR
SCHEMBL1642722 0.77 CDK2 (0.50) KDRRIPK2RIPK3EGFRTRPM5
SCHEMBL13663554 0.77 JAK2 (0.55) JAK2JAK3AURKAAURKBKDR
SCHEMBL13663484 0.77 JAK2 (0.49) JAK2JAK3AURKAAURKBKDR
SCHEMBL13663577 0.77 JAK2 (0.47) JAK2JAK3DHODHIGF1R
SCHEMBL4170159 0.76 DYRK2 (0.39) JAK2JAK3AURKAAURKBKDR
SCHEMBL13663490 0.76 ABCB1 (0.48) JAK2JAK3AURKAAURKBKDR
SCHEMBL13663558 0.76 AURKA (0.54) JAK2JAK3AURKAAURKBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US disclosed
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH MAP3K1, MAP3K15, MAP3K5 JAK2 39/4885JAK3 35/4885AURKA 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback